MedTrace Logo

A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)

NCT05070663 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2025-04-29

No results posted yet for this study

Summary

Primary objective:

\- Describe the characteristics of enrolled severe asthma patients

Secondary objectives:

* Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year
* Assess the clinical objectives of the asthma care
* Assess comorbidities associated with Type 2 inflammation
* Assess safety during the year of treatment

Conditions

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2024-03-14
Completion
2025-03-03

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05070663 on ClinicalTrials.gov